Availability of Essential Medicines and Drugs for treatment of chronic disease in the pharmacies of Nepal during COVID 19 Pandemic
Keywords:
Pandemic, Chronic disease, Essential drugs, AvailabilityAbstract
Background: The world is experiencing the worst pandemic of recent time. Hospitals are allowing only limited patients in the OPDs. The patients with various chronic diseases are asked to stay in home and are advised to continue taking the prescribed medicines. This study is planned to assess the availability commonly used drugs in pharmacies.
Objectives: the objective of this study was to analyze the availability of drugs for chronic disease and essential medicines in Pharmacies
Methods: The Performa was given to pharmacies around various hospitals of different provinces via medical officers working there. The filled Performa was collected and drug was considered available if it was present in pharmacy at that time. Along will availability of drugs, total number of brands available was also recorded.
Results: Total of 58 pharmacies from all the province were included. Nine pharmacies from province one, 6 pharmacies from province two, 11 pharmacies from Bagmati province, 9 pharmacies from Gandakiprovinve, 12 pharmacies from Lumbini province, 2 pharmacies from Karnali province and 9 pharmacies from Sudhurpachhinm Pradesh were included. Among drugs used in chronic diseases, Amlodipine (94.8%) Metformin (93.1%),Losartan (93.1%), Atorvastatin (93.1%) and Glimeperide (89.7%) were most commonly available drugs in various pharmacies. Among other Essential drugs Paracetamol (100%), Metronidazole (100%), Amoxicillin (100%), Diclofenac( 96.6%), Azithromycin (96.6%), Cetrizine HCL(94.8%%), Albendazole (94.8%), were most commonly present. Highest number of brands available in a pharmacy was of Amlodipine (n=30) followed by losartan (n=20), Telmisartan (n=20), Metformin (n=20), Glimipiride (n=20) and Paracetamol (n=20).
Conclusion: Most of the drugs used for chronic diseases and the essential drugs were available in the pharmacies however more extensive studies including larger number of pharmacies is necessary.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2022 International Journal of Biomedical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- An author must submit Copyright form After acceptance of the article.